0001415889-24-002625.txt : 20240205
0001415889-24-002625.hdr.sgml : 20240205
20240205175505
ACCESSION NUMBER: 0001415889-24-002625
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crockett Thomas Andrew
CENTRAL INDEX KEY: 0001690920
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 24597160
MAIL ADDRESS:
STREET 1: BUILDING 227, TETRICUS SCIENCE PARK
STREET 2: PORTON DOWN, SALISBURY
CITY: WILTSHIRE
STATE: X0
ZIP: SP4 0JQ
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
form4-02052024_100254.xml
X0508
4
2024-02-01
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001690920
Crockett Thomas Andrew
C/O KALVISTA PHARMACEUTICALS, INC.
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
true
true
false
false
CEO
0
Common Stock
2024-02-01
4
S
0
9300
16.1751
D
118232
D
Common Stock
2024-02-01
4
S
0
700
16.8143
D
117532
D
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 31, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $16.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
/s/ Benjamin L. Palleiko, Attorney-in-Fact
2024-02-05